Merck Beat Consensus Revenue and EPS Estimates in Q4

On February 1, Merck (MRK) issued a press release announcing its financial results for the fourth quarter and fiscal 2018.

In the fourth quarter, Merck reported total revenues of $11.0 billion, a rise of 5% YoY (year-over-year) on a reported basis, despite a 3% negative revenue impact attributable to foreign currency fluctuations. The company reported total revenues of $42.29 billion in fiscal 2018—a rise of 5% YoY. Merck beat the consensus revenue estimates in the fourth quarter and fiscal 2018. Read Can Merck Impress Markets with Q4 2018 Results? to learn more.

In the fourth quarter, Merck reported a non-GAAP EPS of $1.04—a rise of 6% YoY. The company reported a non-GAAP diluted EPS of $4.34 in fiscal 2018—a rise of 9% YoY. Merck beat the consensus EPS estimates in the fourth quarter and fiscal 2018. To learn more about Merck’s consensus EPS estimates, read A Look at Merck’s EPS and Expense Estimates for Q4 2018.

Merck has risen 1.64% compared to its previous closing price. Merck is trading at $75.89 in the pre-market trading session on February 1.

Analysts expect Merck to report revenues of $44.53 billion in fiscal 2019. According to Merck’s fourth-quarter earnings press release, the company expects its fiscal 2019 revenues to fall by $43.2 billion–$44.7 billion despite a 1% negative impact due to currency fluctuations.

Analysts also expect Merck to report a non-GAAP EPS of $4.68 in fiscal 2019. According to Merck’s fourth-quarter earnings press release, the company expects its fiscal 2019 adjusted diluted EPS to fall by $4.57–$4.72.